Source: Natali_ Mis/ShutterStock.com
Biotech stocks, particularly those delving into gene editing, have been nothing short of an explosion in the financial market.
We need not look further than CRISPR Therapeutics (CRSP) for validation. Since late October, CRSP’s shares have soared from approximately $40 to about $90.18. This meteoric surge is attributed to much-awaited developments: the affirmative US FDA and European Commission sanctions on CRISPR’s treatments for sickle cell, and transfusion-dependent beta-thalassemia.
Meanwhile, shares of Beam Therapeutics (BEAM) have also undertaken a momentous leap, escalating from roughly $17 to $32.90. Apart from pursuing its own sickle cell treatment, the company is fast-tracking its in vivo program for alpha-1 antitrypsin deficiency (AATD) with a clinical trial application. Bolstering this growth further, JP Morgan recently elevated its outlook on BEAM, enticed by the prospects of its AATD candidate.
Even more promising are other biotech equities that boast similar exponential potential, including:
Intellia Therapeutics (NTLA)
Source: rafapress / Shutterstock.com
In recent days, Intellia Therapeutics (NTLA) surfaced with promising results from its Phase 1 study of NTLA-2002 for hereditary angioedema (HAE) in the New England Journal of Medicine. Though there hasn’t been much excitement surrounding NTLA following this development, patience may prove rewarding. The study revealed that about 90% of patients remained free of attacks after a 16-week primary observation period. If it continues to show progress in its HAE treatment, NTLA could seize an $11 billion opportunity by 2029.
Adding to the fervor, Cathie Wood’s ARK funds have enhanced their stake in NTLA by acquiring an additional 98,000 shares amounting to $2.6 million. Furthermore, NTLA has commenced a collaborative effort with ReCode Therapeutics to devise genomic treatments for cystic fibrosis (CF). As per an official statement released by Intellia, “The strategic alliance aims to concentrate on creating remedies for CF patients with limited or no existing therapeutic options.”
Verve Therapeutics (VERV)
Source: shutterstock.com/Romix Image
Alongside NTLA, Verve Therapeutics (VERV) is a noteworthy mention. As elucidated earlier, it recently “unveiled the results of the clinical trials of its drug VERVE-101. The trials revealed that the single-course in vivo liver base editing medicine led to reductions of disease-causing LDL-C in individuals afflicted with heterozygous familial hypercholesterolemia.”
Although VERV’s trajectory hasn’t been exceptionally eventful thus far, exercising patience could prove valuable. A further triumph could extend relief to the nearly three million individuals in the U.S. and Europe grappling with the disease. According to a company press release, “Verve anticipates the commencement of a Phase 1b clinical trial with VERVE-102 for patients with HeFH in the first half of 2024. Moreover, the company anticipates the initiation of clinical trials for VERVE-201 in the latter half of the year.”
Elaborating on the specificities, “VERVE-201, an in vivo base editing medicine delivered as an intravenous infusion, is aimed at deactivating the ANGPTL3 gene in liver cells, halting liver production of blood ANGPTL3 and thus, durably lessening blood levels of LDL-C and triglyceride-rich lipoproteins.”
Invesco Biotechnology & Genome ETF (PBE)
The Renaissance of Biotech and Genome Stocks: An Opportunity for Investors
Biotech and genome stocks have been a breeding ground for opportunistic investing, and the Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) has been a standout player in this field, boasting holdings such as Illumina(NASDAQ:ILMN), Neurocrine Biosciences (NASDAQ:NBIX), Vertex Pharmaceuticals (NASDAQ:VRTX), and Amgen (NASDAQ:AMGN). Since its dip to $53 in late 2023, the ETF has surged to $64.82, but with the current buzz surrounding biotech and genome stocks, it may not be long until the PBE ETF edges closer to the $75 mark.
A Boon for Diversified Investment
For those seeking to diversify, the PBE ETF, with an expense ratio of 0.58%, provides exposure to 30 biotech and genome stocks, priced at around $64 per share. This diversity presents a compelling proposition for investors looking to gain from the growth potential within the biotech and genome sectors. With substantial holdings in key players in the biotech and genome space, the ETF offers a strategic avenue for investors to gain access to a broad array of companies with promising prospects.
Room for Growth
The upward trajectory showcased by the PBE ETF reflects not only the positive sentiment surrounding biotech and genome stocks but also mounting investor confidence in the sector’s potential to generate appealing returns. The bounce-back from the late 2023 low to a price of $64.82 is telling of the stirring interest and bullish outlook for the industry. For investors eyeing this space, the climb to $75 held as a near-term goal seems both reasonable and tantalizing, given the current fervor around biotech and genome stocks.
An Analyst’s Perspective
Contributing insightful commentary to InvestorPlace.com, Ian Cooper, with over two decades of experience in stock and options analysis, did not hold any positions related to the securities mentioned. His thoughts on the outlined ETF offer compelling insights for investors seeking to make informed decisions in the dynamic realm of biotech and genome stocks.
